Leland L Fan1, Megan K Dishop2, Csaba Galambos2, Frederic B Askin3, Frances V White4, Claire Langston5, Deborah R Liptzin1, Miranda E Kroehl6, Gail H Deutsch7, Lisa R Young8, Geoffrey Kurland9, James Hagood10, Sharon Dell11, Bruce C Trapnell12, Robin R Deterding1. 1. 1 Department of Pediatrics, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, Colorado. 2. 2 Department of Pathology and Laboratory Medicine, University of Colorado School of Medicine, Aurora, Colorado. 3. 3 Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland. 4. 4 Department of Pathology, Washington University School of Medicine, St. Louis, Missouri. 5. 5 Department of Pathology, Baylor College of Medicine, Houston, Texas. 6. 6 Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado, Aurora, Colorado. 7. 7 Department of Pathology, University of Washington School of Medicine, Seattle, Washington. 8. 8 Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee. 9. 9 Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. 10. 10 Department of Pediatrics, University of California San Diego and Rady Children's Hospital, San Diego, California. 11. 11 Department of Pediatrics, The Hospital of Sick Children, Toronto, Ontario, Canada; and. 12. 12 Department of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Abstract
RATIONALE: Children's Interstitial and Diffuse Lung Disease (chILD) is a heterogeneous group of disorders that is challenging to categorize. In previous study, a classification scheme was successfully applied to children 0 to 2 years of age who underwent lung biopsies for chILD. This classification scheme has not been evaluated in children 2 to 18 years of age. OBJECTIVES: This multicenter interdisciplinary study sought to describe the spectrum of biopsy-proven chILD in North America and to apply a previously reported classification scheme in children 2 to 18 years of age. Mortality and risk factors for mortality were also assessed. METHODS: Patients 2 to 18 years of age who underwent lung biopsies for diffuse lung disease from 12 North American institutions were included. Demographic and clinical data were collected and described. The lung biopsies were reviewed by pediatric lung pathologists with expertise in diffuse lung disease and were classified by the chILD classification scheme. Logistic regression was used to determine risk factors for mortality. MEASUREMENTS AND MAIN RESULTS: A total of 191 cases were included in the final analysis. Number of biopsies varied by center (5-49 biopsies; mean, 15.8) and by age (2-18 yr; mean, 10.6 yr). The most common classification category in this cohort was Disorders of the Immunocompromised Host (40.8%), and the least common was Disorders of Infancy (4.7%). Immunocompromised patients suffered the highest mortality (52.8%). Additional associations with mortality included mechanical ventilation, worse clinical status at time of biopsy, tachypnea, hemoptysis, and crackles. Pulmonary hypertension was found to be a risk factor for mortality but only in the immunocompetent patients. CONCLUSIONS: In patients 2 to 18 years of age who underwent lung biopsies for diffuse lung disease, there were far fewer diagnoses prevalent in infancy and more overlap with adult diagnoses. Immunocompromised patients with diffuse lung disease who underwent lung biopsies had less than 50% survival at time of last follow-up.
RATIONALE: Children's Interstitial and Diffuse Lung Disease (chILD) is a heterogeneous group of disorders that is challenging to categorize. In previous study, a classification scheme was successfully applied to children 0 to 2 years of age who underwent lung biopsies for chILD. This classification scheme has not been evaluated in children 2 to 18 years of age. OBJECTIVES: This multicenter interdisciplinary study sought to describe the spectrum of biopsy-proven chILD in North America and to apply a previously reported classification scheme in children 2 to 18 years of age. Mortality and risk factors for mortality were also assessed. METHODS:Patients 2 to 18 years of age who underwent lung biopsies for diffuse lung disease from 12 North American institutions were included. Demographic and clinical data were collected and described. The lung biopsies were reviewed by pediatric lung pathologists with expertise in diffuse lung disease and were classified by the chILD classification scheme. Logistic regression was used to determine risk factors for mortality. MEASUREMENTS AND MAIN RESULTS: A total of 191 cases were included in the final analysis. Number of biopsies varied by center (5-49 biopsies; mean, 15.8) and by age (2-18 yr; mean, 10.6 yr). The most common classification category in this cohort was Disorders of the Immunocompromised Host (40.8%), and the least common was Disorders of Infancy (4.7%). Immunocompromised patients suffered the highest mortality (52.8%). Additional associations with mortality included mechanical ventilation, worse clinical status at time of biopsy, tachypnea, hemoptysis, and crackles. Pulmonary hypertension was found to be a risk factor for mortality but only in the immunocompetent patients. CONCLUSIONS: In patients 2 to 18 years of age who underwent lung biopsies for diffuse lung disease, there were far fewer diagnoses prevalent in infancy and more overlap with adult diagnoses. Immunocompromised patients with diffuse lung disease who underwent lung biopsies had less than 50% survival at time of last follow-up.
Authors: Jennifer J Soares; Gail H Deutsch; Paul E Moore; Mohammad F Fazili; Eric D Austin; Rebekah F Brown; Andrew G Sokolow; Melissa A Hilmes; Lisa R Young Journal: Pediatrics Date: 2013-09-30 Impact factor: 7.124
Authors: William D Travis; Ulrich Costabel; David M Hansell; Talmadge E King; David A Lynch; Andrew G Nicholson; Christopher J Ryerson; Jay H Ryu; Moisés Selman; Athol U Wells; Jurgen Behr; Demosthenes Bouros; Kevin K Brown; Thomas V Colby; Harold R Collard; Carlos Robalo Cordeiro; Vincent Cottin; Bruno Crestani; Marjolein Drent; Rosalind F Dudden; Jim Egan; Kevin Flaherty; Cory Hogaboam; Yoshikazu Inoue; Takeshi Johkoh; Dong Soon Kim; Masanori Kitaichi; James Loyd; Fernando J Martinez; Jeffrey Myers; Shandra Protzko; Ganesh Raghu; Luca Richeldi; Nicola Sverzellati; Jeffrey Swigris; Dominique Valeyre Journal: Am J Respir Crit Care Med Date: 2013-09-15 Impact factor: 21.405
Authors: Lisa R Young; Bruce C Trapnell; Kenneth D Mandl; Daniel T Swarr; Jennifer A Wambach; Carol J Blaisdell Journal: Ann Am Thorac Soc Date: 2016-12
Authors: Whitney B Eldridge; Qunyuan Zhang; Albert Faro; Stuart C Sweet; Pirooz Eghtesady; Aaron Hamvas; F Sessions Cole; Jennifer A Wambach Journal: J Pediatr Date: 2017-02-16 Impact factor: 4.406
Authors: Paul E Moore; Jason T Poston; Debra Boyer; Emily Barsky; Jonathan Gaffin; Kathleen B Boyne; Kristie R Ross; Laura Beth Mann Dosier; Timothy J Vece; Alicia M Casey; Sebastian K Welsh; J Wells Logan; Edward G Shepherd; Pelton A Phinzy; Howard B Panitch; Christina M Papantonakis; Eric D Austin; Amir B Orandi; Maleewan Kitcharoensakkul; Mark K Abe; Amjad Horani; Jordan S Rettig; Jessica Pittman Journal: Ann Am Thorac Soc Date: 2017-08
Authors: Robin R Deterding; Emily M DeBoer; Michal J Cidon; Terry E Robinson; David Warburton; Gail H Deutsch; Lisa R Young Journal: Am J Respir Crit Care Med Date: 2019-11-15 Impact factor: 21.405
Authors: Anne B Chang; John J Oppenheimer; Miles Weinberger; Cameron C Grant; Bruce K Rubin; Richard S Irwin Journal: Chest Date: 2017-06-21 Impact factor: 9.410
Authors: Joseph Jacob; Catherine M Owens; Alan S Brody; Thomas Semple; Tom A Watson; Alistair Calder; Pilar Garcia-Peña; Paolo Toma; Anand Devaraj; Henry Walton; Antonio Moreno-Galdó; Paul Aurora; Alexandra Rice; Timothy J Vece; Steve Cunningham; Andre Altmann; Athol U Wells; Andrew G Nicholson; Andrew Bush Journal: ERJ Open Res Date: 2019-07-29
Authors: Christopher T Towe; Frances V White; R Mark Grady; Stuart C Sweet; Pirooz Eghtesady; Daniel J Wegner; Partha Sen; Przemyslaw Szafranski; Pawel Stankiewicz; Aaron Hamvas; F Sessions Cole; Jennifer A Wambach Journal: J Pediatr Date: 2017-12-01 Impact factor: 4.406